Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AVID-37Rx
- Development stage
- Preclinical
- Lead developer
- AdCure Bio
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Gene Therapies
- Administration
- Intravenous
01
Overview
AVID-37Rx is an engineered oncolytic adenovirus developed by AdCure Bio for the systemic treatment of residual disease in solid cancers, including non-small cell lung cancer (NSCLC). As an oncolytic virus therapy, it is designed to selectively infect and lyse tumor cells. Unlike many oncolytic viruses that require intratumoral injection, AVID-37Rx is intended for intravenous administration, allowing it to target disseminated residual disease following primary treatment. It is currently in the preclinical discovery phase.
- Other names
- AVID-37RxAVID37RxAVID 37Rx
Beyond the preview
Go deeper on AVID-37Rx.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AVID-37Rx.